Dry eye disease: Unlocking solutions for the most stubborn cases
The quest for effective treatments in ophthalmology is an ever-evolving journey, and dry eye disease (DED) is a complex condition that often leaves patients and doctors alike searching for answers. But what happens when DED becomes a seemingly insurmountable challenge? When patients have tried multiple treatments to no avail, and the root cause remains elusive? This is where the expertise of leading ophthalmologists shines, as they delve into the intricacies of managing today's most complex ocular surface cases.
The Evolving Landscape of DED Management:
Ophthalmologists are pushing the boundaries of what's possible in treating DED and ocular surface disease, especially with an aging patient population and increasing systemic comorbidities. The Eye Care Network sought insights from renowned experts in the field, aiming to uncover emerging strategies and technologies that are shaping modern management approaches. This Q&A session delves into the fascinating world of refractory cases, the potential of new biologic and topical therapies, and the advancements in diagnostic precision that promise to transform tear-film and ocular-surface assessment.
Expert Insights:
Christopher E. Starr, MD, an associate professor of ophthalmology and director of refractive surgery and ophthalmic education at Weill Cornell Medicine, New York-Presbyterian Hospital, offers a bold perspective. He believes that all DED/ocular surface disease (OSD) cases are treatable, but it requires a comprehensive approach and time. Dr. Starr emphasizes the importance of managing systemic conditions like autoimmune diseases that may contribute to DED. Interestingly, he suggests that when patients report refractory dry eye, it often indicates an alternate diagnosis, with neuropathic corneal pain syndrome being a common culprit in his experience.
William Trattler, MD, a refractive, corneal, and cataract eye surgeon at the Center For Excellence In Eye Care in Miami, FL, provides a practical approach for severe dry eye cases. He recommends starting with therapies to increase tear volume, such as canalicular gel, followed by anti-inflammatory medications. Dr. Trattler also highlights the benefits of focusing on the eyelids and the tear film's lipid layer. He introduces a new topical therapy, acoltremon, a neuromodulator eye drop that stimulates basal tear secretion. For the most challenging cases, he suggests advanced therapies like serum tears and amniotic membranes.
The Promise of Biologics and Topical Therapies:
When it comes to biologics and topical therapies, Dr. Starr is enthusiastic about novel compounds with unique mechanisms. He highlights acoltremon (Tryptyr) and perfluorohexyloctane (Miebo) as recent FDA-approved medications with exciting potential. Additionally, he expresses interest in Azura Ophthalmic's selenium sulfide treatment for meibomian gland dysfunction and AbbVie/Aldeyra's reproxolap. Dr. Starr also advocates for autologous serum drops, considering them the ultimate 'self-biologic' therapy.
Diagnostic Technology: Unlocking Personalized Treatment:
Diagnostic tools play a pivotal role in DED management, and Dr. Starr values their complementarity to a standardized slit lamp exam. Osmolarity and MMP-9 testing, along with meibography, have been long-standing components of his DED/OSD workup. He also expresses interest in noninvasive tear break-up time (TBUT) and lactoferrin/IgE testing. The Brill noncontact esthesiometer has been a game-changer, enabling earlier diagnosis of neuropathic ocular/corneal pain and neurotrophic keratitis.
The Future of Tear Film and Ocular Surface Assessment:
While Dr. Starr is unaware of any imminent novel tear film imagers or diagnostic tests, the field is ever-evolving. The continuous development of diagnostic technologies and treatment options offers hope for improved patient outcomes.
And here's a thought-provoking question: In the pursuit of effective DED management, how can we strike a balance between embracing innovative therapies and ensuring patient safety? Are there potential risks associated with the rapid advancement of treatments that we should be aware of? Share your insights and experiences in the comments below, and let's explore the fascinating world of ophthalmology together.
